Suchergebnisse - "Zhou, Jianying"

PubPharm (39)

1

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study

enthalten in: Cancer communications (London, England) | 2024

von Zheng, J. | Wang, T. | Yang, Y. | +41

2

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer : a multicentre, open-label, randomised phase 3 study

enthalten in: The Lancet. Respiratory medicine | 2023

von Lu, S. | Zhou, J. | Jian, H. | +41

CommentIn: Lancet Respir Med. 2023 Oct;11(10):857-859. - PMID 37244264

3

Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study : a case report

enthalten in: Anti-cancer drugs | 2023

von Wu, L. | Cheng, Y. | Huang, D. | +7

4

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer : a randomized, multicenter, open-label, phase III trial

enthalten in: Signal transduction and targeted therapy | 2023

von Yang, Y. | Min, J. | Yang, N. | +17

5

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC : Phase 1 Study Results

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Li, Z. | Song, Z. | Zhao, Y. | +23

CommentIn: J Thorac Oncol. 2023 Jul;18(7):844-846. - PMID 37348992

6

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation : A pooled analysis of two clinical studies

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Yang, S. | Wu, S. | Zhao, Y. | +54

7

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification : INSIGHT Final Analysis

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Liam, C. | Ahmad, A. | Hsia, T. | +13

8

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer : a pooled analysis from two phase 2 studies

enthalten in: BMC medicine | 2023

von Hu, X. | Zhang, S. | Ma, Z. | +27

9

Neoadjuvant ceritinib treatment achieved pathological complete response in patients with anaplastic lymphoma kinase positive stage IIIA-N2 non-small cell lung cancer

enthalten in: Chinese medical journal | 2023

von Shen, Q. | Gao, Q. | Zhou, J.

10

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

enthalten in: BMC medicine | 2023

von Shi, Y. | Zhou, J. | Zhao, Y. | +13